High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours.
about
The Robyn Barst Memorial Lecture: Differences between the fetal, newborn, and adult pulmonary circulations: relevance for age-specific therapies (2013 Grover Conference series)Understanding the basis for Down syndrome phenotypes.Hypothesis: primary antiangiogenic method proposed to treat early stage breast cancerNew concepts in breast cancer emerge from analyzing clinical data using numerical algorithmsMolecular regulation of tumor angiogenesis and perfusion via redox signaling.Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressorsTamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo.Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathologySurvival and morbidity outcomes for very low birth weight infants with Down syndromeIncreased survival following tumorigenesis in Ts65Dn mice that model Down syndrome.Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular MatrixIncreased Lung Expression of Anti-Angiogenic Factors in Down Syndrome: Potential Role in Abnormal Lung Vascular Growth and the Risk for Pulmonary HypertensionEndostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition.The clinical potential of antiangiogenic fragments of extracellular matrix proteinsInter-Dependent Mechanisms Behind Cognitive Dysfunction, Vascular Biology and Alzheimer's Dementia in Down Syndrome: Multi-Faceted Roles of APPMutations in collagen 18A1 and their relevance to the human phenotype.Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengersMolecular analysis of collagen XVIII reveals novel mutations, presence of a third isoform, and possible genetic heterogeneity in Knobloch syndromeMalignancy in children with trisomy 21.Down's syndrome: protection against cancer and the therapeutic potential of DSCR1.Tumor angiogenesis: insights and innovations.The effect of RCAN1 on the biological behaviors of small cell lung cancer.Low risk of solid tumors in persons with Down syndrome.Endostatin as a Biomarker of Basement Membrane Degradation.Endostatin binds nerve growth factor and thereby inhibits neurite outgrowth and neuronal migration in-vitro.Does the association between serum endostatin, an endogenous anti-angiogenic protein, and acute myocardial infarction differ by race?COL18A1 is highly expressed during human adipocyte differentiation and the SNP c.1136C > T in its "frizzled" motif is associated with obesity in diabetes type 2 patients.Endostatin: a promising biomarker in the cardiovascular continuum?An extracellular proteasome releases endostatin from human collagen XVIII.Breast cancer surveillance in women with intellectual disabilities
P2860
Q26862046-78A270A9-6B98-4ECD-A2FB-FAAB84F7CD64Q33238943-46532DE3-77C9-4E79-A3B6-12664447E325Q33398689-B41E9393-2A3E-4503-9A6B-286E272210E7Q33445553-192C01F8-5590-4392-BF70-52608F1C78E5Q33572306-49FEABA1-0044-4297-BC65-BE40BB4B7018Q33864448-2B4EE7DB-7BC5-48FD-B987-894CA02AC09AQ34044998-106FF1F0-13C6-43EB-B5C0-5F87C734B830Q34611232-64D98ACF-2AA4-4932-92B5-8D03E9F487BBQ34689254-7890F993-86A8-4DB0-955B-243D451C9F76Q34988075-53B1BCE6-B1D6-4C6E-AA71-7AB823EA4308Q35140747-07326267-31B1-463D-8C59-183B42B9546AQ35609350-5D231FB7-62DA-4202-A513-63B0F3E006B8Q35679807-7F9CE77F-4FCF-442E-AC65-5E236E1E81F0Q36093897-C2A630E7-DBB8-4080-8F1E-D7A1AE07C2A0Q36094099-A5BCA55F-D7F5-4D6F-9782-E11AEB29A6C0Q36290509-DA7D187D-AF39-4ECD-B9F3-881A314A7ACEQ36332872-6AAC505E-925A-44D4-AB0C-F57DFD590B73Q36419264-A8D713B4-A0FD-4444-8378-B202A788BB55Q36578668-96DABF80-8384-4764-859D-2580DBB03F2FQ37203797-67C18CE6-D13D-4262-9EF1-2EE1150AD022Q37379570-8937FECB-2910-4B34-A7AA-13F349166D66Q37620385-2C6EA4AD-2D00-4430-B60B-57DD28DA3659Q37743207-ABB7EFF7-CA90-4A91-9A0E-39AFF2969E69Q38699703-DB445D3C-4522-4E09-80EB-D30A933EC14DQ40506069-461137FF-7246-42DF-91CF-733E652212D0Q42629571-C58AA98C-62FF-4215-958C-506BD70EFA5EQ43042279-8DA5B6FA-931A-4B56-917B-4507818CEC44Q46413991-155786F8-15EB-47A8-9043-0A52C7E45CC2Q46698087-38AFDA4D-4F32-476C-AEE8-9783EE134503Q47667458-99231998-9C89-48FD-B277-8FEDA46E1666Q51283766-A7F706A6-AEC7-4269-89F6-F81946A73847Q58207517-76892F56-79CF-4EDD-BB82-C3E98D9D6836
P2860
High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
High serum endostatin levels i ...... d prevention of solid tumours.
@ast
High serum endostatin levels i ...... d prevention of solid tumours.
@en
High serum endostatin levels i ...... d prevention of solid tumours.
@nl
type
label
High serum endostatin levels i ...... d prevention of solid tumours.
@ast
High serum endostatin levels i ...... d prevention of solid tumours.
@en
High serum endostatin levels i ...... d prevention of solid tumours.
@nl
prefLabel
High serum endostatin levels i ...... d prevention of solid tumours.
@ast
High serum endostatin levels i ...... d prevention of solid tumours.
@en
High serum endostatin levels i ...... d prevention of solid tumours.
@nl
P2093
P356
P1476
High serum endostatin levels i ...... d prevention of solid tumours.
@en
P2093
Moreira-Filho CA
Mustacchi Z
Passos-Bueno MR
P2888
P304
P356
10.1038/SJ.EJHG.5200721
P50
P577
2001-11-01T00:00:00Z